other material
confidence high
sentiment negative
materiality 0.65
Acumen Pharmaceuticals files preliminary prospectus for common stock offering; reports $172.2M cash as of June 30, 2023
Acumen Pharmaceuticals, Inc.
- Company plans to offer shares of common stock; no terms disclosed.
- Preliminary cash and cash equivalents and marketable securities total $172.2M as of June 30, 2023.
- Financial results for Q2 2023 are preliminary and subject to completion; actual results may differ materially.